EWTX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
61.9M
+14.5%
54.1M
-3.3%
56.0M
+19.5%
46.9M
+10.0%
42.6M
R&D
47.5M
+11.5%
42.7M
-2.2%
43.6M
+16.3%
37.5M
+11.7%
33.6M
SG&A
14.4M
+25.6%
11.5M
-7.4%
12.4M
+32.1%
9.4M
+3.6%
9.1M
Operating Income
-61943000
-14.5%
-54115000
+3.3%
-55979000
-19.5%
-46858000
-10.0%
-42610000
EBITDA
-61402000
-14.6%
-53578000
+3.4%
-55454000
-19.7%
-46335000
-10.1%
-42087000
Net Income
-57327000
-17.0%
-49013000
+2.4%
-50216000
-23.5%
-40666000
-12.6%
-36115000
EPS (Basic)
$-0.53
-15.2%
$-0.46
+2.1%
$-0.47
-20.5%
$-0.39
-14.7%
$-0.34
EPS (Diluted)
$-0.53
-15.2%
$-0.46
+2.1%
$-0.47
-20.5%
$-0.39
-14.7%
$-0.34
Shares (Diluted)
107.7M
+0.5%
107.1M
+0.9%
106.2M
+0.6%
105.5M
+0.5%
104.9M
Edgewise Therapeutics (EWTX) โ€” Financials